Malignant Transformation of Neurocutaneous Melanosis (NCM) Following Immunosuppression

Overview

Journal Pediatr Dermatol

Publisher Wiley

Specialties Dermatology
Pediatrics

Date 2019 Mar 15

PMID 30868657

Citations 4

Authors

Lauren R Schaff

Ashfaq Marghoob

Marc K Rosenblum

Rina Meyer

Yasmin Khakoo

Affiliations

Soon will be listed here.

Abstract

Neurocutaneous melanosis (NCM) is the condition of abnormal melanocyte deposition in the leptomeninges and brain parenchyma. Associated with congenital melanocytic nevi, NCM can result in neurologic deficits, hydrocephalus, and rarely, malignant transformation of cells. We present the case of a 16-year-old boy with NCM who developed malignant leptomeningeal melanoma following immunosuppression with a TNFα inhibitor. To our knowledge, this is the first reported case of a patient with known NCM undergoing malignant transformation after anti-TNF therapy for inflammatory bowel disease.

Citing Articles

Neurocutaneous Melanosis with Meningeal Melanocytosis: A Rare Case of Intracranial Hypertension and Cutaneous Manifestations.

Chen H, Hsu T, Chao T, Yang S Life (Basel). 2024; 14(1).

PMID: 38255754 PMC: 10817463. DOI: 10.3390/life14010139.

Neurocutaneous melanocytosis-associated malignant melanoma presenting with peritoneal seeding.

Sener U, Elmore K, Jayaseelan K, Porter J, Marghoob A, Rosenblum M Pediatr Dermatol. 2021; 38(5):1298-1301.

PMID: 34463389 PMC: 9429811. DOI: 10.1111/pde.14789.

Cutaneous Melanomas Arising during Childhood: An Overview of the Main Entities.

De la Fouchardiere A, Boivin F, Etchevers H, Macagno N Dermatopathology (Basel). 2021; 8(3):301-314.

PMID: 34449585 PMC: 8395919. DOI: 10.3390/dermatopathology8030036.

Symptomatic neurocutaneous melanosis: mild clinical onset in a teenager.

Vanood A, Lee Y, Leleszi E, Krishnan A BMJ Case Rep. 2020; 13(11).

PMID: 33257354 PMC: 7705374. DOI: 10.1136/bcr-2020-235772.

References

Hale E, Stein J, Ben-Porat L, Panageas K, Eichenbaum M, Marghoob A . Association of melanoma and neurocutaneous melanocytosis with large congenital melanocytic naevi--results from the NYU-LCMN registry. Br J Dermatol. 2005; 152(3):512-7. DOI: 10.1111/j.1365-2133.2005.06316.x. View

Bongartz T, Sutton A, Sweeting M, Buchan I, Matteson E, Montori V . Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006; 295(19):2275-85. DOI: 10.1001/jama.295.19.2275. View

Fulchiero Jr G, Salvaggio H, Drabick J, Staveley-OCarroll K, Billingsley E, Marks J . Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol. 2007; 56(5 Suppl):S65-7. DOI: 10.1016/j.jaad.2006.12.024. View

Larmonier N, Cathelin D, Larmonier C, Nicolas A, Merino D, Janikashvili N . The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model. Exp Cell Res. 2007; 313(11):2345-55. DOI: 10.1016/j.yexcr.2007.03.027. View

Kinsler V, Chong W, Aylett S, Atherton D . Complications of congenital melanocytic naevi in children: analysis of 16 years' experience and clinical practice. Br J Dermatol. 2008; 159(4):907-14. DOI: 10.1111/j.1365-2133.2008.08775.x. View

Kadonaga J, Frieden I . Neurocutaneous melanosis: definition and review of the literature. J Am Acad Dermatol. 1991; 24(5 Pt 1):747-55. DOI: 10.1016/0190-9622(91)70115-i. View

Khan I, Rahman L, McKenna D . Primary cutaneous melanoma: a complication of infliximab treatment?. Clin Exp Dermatol. 2009; 34(4):524-6. DOI: 10.1111/j.1365-2230.2008.02970.x. View

Katoulis A, Kanelleas A, Zambacos G, Panayiotides I, Stavrianeas N . Development of two primary malignant melanomas after treatment with adalimumab: a case report and review of the possible link between biological therapy with TNF-alpha antagonists and melanocytic proliferation. Dermatology. 2010; 221(1):9-12. DOI: 10.1159/000300136. View

Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A . Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 2010; 62(8):2517-24. DOI: 10.1002/art.27511. View

10.

Long M, Martin C, Pipkin C, Herfarth H, Sandler R, Kappelman M . Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012; 143(2):390-399.e1. PMC: 4065572. DOI: 10.1053/j.gastro.2012.05.004. View

11.

Kouklakis G, Efremidou E, Pitiakoudis M, Liratzopoulos N, Polychronidis A . Development of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn's disease: a case report and review of the hypothetical association between TNF-α blockers and cancer. Drug Des Devel Ther. 2013; 7:195-9. PMC: 3615922. DOI: 10.2147/DDDT.S41889. View

12.

Singh S, Nagpal S, Murad M, Yadav S, Kane S, Pardi D . Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013; 12(2):210-8. DOI: 10.1016/j.cgh.2013.04.033. View

13.

Salgado C, Basu D, Nikiforova M, Bauer B, Johnson D, Rundell V . BRAF mutations are also associated with neurocutaneous melanocytosis and large/giant congenital melanocytic nevi. Pediatr Dev Pathol. 2014; 18(1):1-9. DOI: 10.2350/14-10-1566-OA.1. View

14.

Bekiesinska-Figatowska M, Sawicka E, Zak K, Szczygielski O . Age related changes in brain MR appearance in the course of neurocutaneous melanosis. Eur J Radiol. 2016; 85(8):1427-31. DOI: 10.1016/j.ejrad.2016.05.014. View

15.

Penn I . Malignant melanoma in organ allograft recipients. Transplantation. 1996; 61(2):274-8. DOI: 10.1097/00007890-199601270-00019. View